33543-18-9

Upstream product

• 42747-41-1 trimethyl-2,5,5-cyclohexene-2-one-1 
• 1125-11-7 methyldimedone 
• 563-20-2 5,5-dimethylcyclohexane-1,2-dione 
• 74-88-4 methyl iodide 
• 1073-13-8 4,4-dimethylcyclohexenone 
• 39776-34-6 3-chloro-2,5,5-trimethyl-cyclohex-2-enone 
• 2979-19-3 3,3-dimethylcyclohexanone 
• 93499-96-8 (E)-2-((dimethylamino)methylene)-5,5-dimethylcyclohexanone 
• 23438-77-9 3,6,6-trimethyl-2-cyclohexen-1-one 
• 59270-16-5 2,5,5-Trimethylcyclohex-2-en-1-ol 
• 60934-84-1 (1,4,4-trimethylcyclohex-2-en-1-ol) 

Downstream Products

• 35482-84-9 4a,7,7-Trimethyl-2-oxo-2,3,4,4a,5,6,7,8-octahydro-naphthalene-1-carboxylic acid ethyl ester 
• 16778-23-7 2,5,5-Trimethyl-2-allyl-cyclohexanon 
• 852247-48-4 ((S)-1-Phenyl-ethyl)-(2,5,5-trimethyl-cyclohex-1-enyl)-amine 
• 15189-14-7 2,2,5,5-tetramethylcyclohexanone 
• 1259014-71-5 methyl 3-(1-hydroxy-2,2,5-trimethylcyclohexyl)propiolate 

Relevant academic research and scientific papers

Selective α-Methylation of Ketones

The convenient and scalable preparative approach for the two-step α-methylation of ketones is described. The optimized protocols for regioselective preparation of enaminones with further diastereoselective and functional groups tolerant hydrogenation to α-methylketones are developed. The scope and limitations of the proposed methodology are discussed. The advantages compared to known procedures are demonstrated. The unexpected role of acetone in the hydrogenation is suggested. The evaluation of the method for both early building block synthesis and late-stage CH-functionalization is shown. The elaborate procedures' preparability and scalability are demonstrated by the synthesis of several α-methyl ketones up to 100 g amount.

OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE

Compounds and compositions of said compounds along with methods of use of compounds are disclosed for treating ophthalmic conditions related to mislocalization of opsin proteins, the misfolding of mutant opsin proteins and the production of toxic visual cycle products that accumulate in the eye. Compounds and compositions useful in the these methods, either alone or in combination with other therapeutic agents, are also described.

Pyrrolopyrazinyl Urea Kinase Inhibitors

The present invention relates to the use of novel pyrrolopyrazinyl urea derivatives of Formula I, wherein the variables R1, R2, R3, R4, and R5 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.